Nina Lindblom has more than 25 years of experience in the pharmaceutical industry working with drug development at biotech companies and at clinical research organizations. She is a member of the Board of Directors of Ultupharma AB and is Head Business and Clinical development at Curovir AB. Dr Lindblom currently serves as Acting CEO of Simplexia since October 2025, she has served on the board of Simplexia AB since 2021.

Lindvi Gudmundsdotter joined Simplxia in 2024. She holds a PhD in Medical Science from the Karolinska Institute. She has over 15 years of experience from the life science industry coupled with deep knowledge of biopharmaceuticals, ranging from vaccines to advanced therapeutics used in precision medicine. Her broad expertise spans translational medicine, regulatory affairs, research and development, IP and the implementation of innovative technologies in healthcare. She has previously held Director positions at Strike Pharma and Affibody AB.

Jan Pilebjer, has more than 40 years of experience from leading positions within the Life Sciences industry, in global as well as smaller start-up enterprises (e.g. Upjohn, Kabi Vitrum, Baxter, Biopool, Medirox and Nycomed). His role has been global and he’s been located to Sweden, Switzerland, USA and Denmark. After returning to Sweden he worked as business coach, within GU Ventures, to start up and coach entrepreneurial life science ventures. Among those Simplexia AB. He’s been instrumental in introducing a number of companies to stock exchanges and also been taking up the CEO position in such. Jan Pilebjer also has been a member of number of Board of Directors to smaller companies. He served as interim CEO for Simplexia for several years after the company was registered. Mr. Pilebjer has served on the board of Simplexia AB since its inception 2017.

Jacob Westman is Associate Professor in Organic Chemistry from Stockholm University and have 35 years experience in the pharmaceutical industry working with a wast number of companies, disease indications and compound classes. He is the inventor of >50 patent families from which a number of novel original compounds have been taken into clinical trials.

Lena Degling Wikingsson has over 30 years of experience in the pharmaceutical industry and has previously been CEO of Independent Pharmaceutica AB and Avaris AB, a non-executive Director of Avaris AB, held positions at SBL Vaccines, Accuro Immunology, and worked as a biotechnology assessor at the Swedish Medical Products Agency. She has broad experience in regulatory affairs and the development of biologics and vaccines. Dr Degling Wikingsson is CEO of Dilafor AB. She joined the Simplexia project in 2010 and has been the Chairman of the board of Simplexia from the company inception in 2017.

Jorma Hinkula leads a research group working on the infection immunology and medical microbiology of experimental vaccines and antiviral drugs. He received his PhD from the Karolinska Institute in 1993. He has served on the board of Simplexia AB since 2023.

Nina Lindblom has more than 25 years of experience in the pharmaceutical industry working with drug development at biotech companies and at clinical research organizations. She is a member of the Board of Directors of Ultupharma AB and is Head Business and Clinical development at Curovir AB. Dr Lindblom currently serves as Acting CEO of Simplexia since October 2025, she has served on the board of Simplexia AB since 2021.

Helena Lundquist has nearly 25 years of experience from the pharmaceutical industry in various business-related roles and therapeutic areas for companies such as Pfizer and Janssen. Mrs Lundquis’s current position is at GU Ventures where she is a member of the Business Development team. She has served on the board of Simplexia AB since 2023.

Jan Pilebjer, has more than 40 years of experience from leading positions within the Life Sciences industry, in global as well as smaller start-up enterprises (e.g. Upjohn, Kabi Vitrum, Baxter, Biopool, Medirox and Nycomed). His role has been global and he’s been located to Sweden, Switzerland, USA and Denmark. After returning to Sweden he worked as business coach, within GU Ventures, to start up and coach entrepreneurial life science ventures. Among those Simplexia AB. He’s been instrumental in introducing a number of companies to stock exchanges and also been taking up the CEO position in such. Jan Pilebjer also has been a member of number of Board of Directors to smaller companies. He served as interim CEO for Simplexia for several years after the company was registered. Mr. Pilebjer has served on the board of Simplexia AB since its inception 2017.

Ola Rönn is a specialist in Internal Medicine and was appointed Associate Professor of Medicine in 1984. After 14 years in academic medicine Dr Rönn joined the pharmaceutical industry. He has worked at Hoechst Roussel and Kabi Pharmacia and Pharmacia Upjohn in different senior R&D positions. Thereafter, he has worked at Astra Zeneca first as Site head of Clinical R&D and Global Director of Drug Safety. His last positions at Astra Zeneca were Global Vice President and head of Gastrointestinal Therapy and Global Vice President Gastrointestinal Scientific Affairs. Since then Dr Rönn has been working as an independent consultant mainly for the pharma industry and has been a board member and chairman in pharmaceutical start-up companies. Dr Rönn joined the Simplexia project in 2009. He has served on the board of Simplexia AB since its inception 2017.

Magnus Sävenhed has worked within the pharmaceutical industry, primarily within process development and manufacturing since his graduation in 1999. Between 2018 and 2024, Mr Sävenhed was Managing Director of Novavax´s site in Uppsala, Sweden. During this period, the company developed a Covid-19 vaccine and obtained approval for commercial sale. Over the period of more than 25 years, he has held several senior positions within the industry. Since 2024, Magnus Sävenhed is CEO of TdB Labs. He joined the Simplexia AB board in 2025.

Fredrik Westin currently seves as CFO and deputy CEO at Claesson & Anderzén AB. Mr Westin’s previous positions include CFO and deputy CEO at Magnolia Bostad, Financial Director at Kungsleden, Analysis Director at GE Capital Real Estate Nordic. He joined the Simplexia AB board in 2025.

Jan-Åke Liljeqvist is the inventor of Simplexia’s HSV-2 vaccine and leads Simplexia’s laboratory research at Gothenburg University. He is senior physician at the Virology Department at Sahlgrenska University Hospital and associate professor at Gothenburg University. He has been working with the vaccine antigen gG-2 since 1995, presenting his thesis 2000.

He has published several papers in the field together with the two other founders in Simplexia, Tomas Bergström and Staffan Görander.

Tomas Bergström is the co-founder of the vaccine project. By training, he is a Specialist Physician in Infectious Diseases, and in Clinical Virology. Since 2000, he is Professor in Clinical Microbiology at the University of Gothenburg, and a Senior Physician at Sahlgren´s University Hospital in Gothenburg. He heads a research group active in basic science and diagnostics of herpesviruses and respiratory viruses and has published >250 scientific papers. He is an advisor to the Swedish Center of Disease Control (Folkhälsomyndigheten) regarding these viruses.

Staffan Görander is a co-founder of the vaccine project. He is senior physician at the virology section at Sahlgrenska University Hospital and a member of the department of infectious diseases at Gothenburg University. He is the first author of the two key scientific publication describing Simplexia’s vaccine approach. He has published several additional papers in the field together with the two other founders of  Simplexia, Tomas Bergström and Jan-Åke Liljeqvist.